Radiation monitoring device patent for RadiaDyne

RadiaDyne announced the issuance of US Patent 9,833,637, a skin patch dosimeter, which relates to the monitoring of skin radiation dose delivered during cancer treatment.

“This issuance of this patent provides broad protection for our unique sensor delivery devices for skin applications related to the OARtrac patient radiation dose monitoring platform, and continues to build on our robust IP portfolio,” said John Isham, RadiaDyne’s founder.

Tamsen Valoir, RadiaDyne’s legal counsel at Boulware & Valoir, said: “We are pleased with the issuance of claims for this submission and look forward to submitting additional applications as RadiaDyne continues to develop new clinical devices for their OARtrac system.”

Bret Boudousquie, RadiaDyne’s President, said: “We are excited Radiation Oncologists can now routinely monitor skin radiation dose for many types of cancer treatments in real-time, which is vital for the best possible clinical results.”